{
    "clinical_study": {
        "@rank": "111092", 
        "acronym": "RISU", 
        "arm_group": [
            {
                "arm_group_label": "Krill oil", 
                "arm_group_type": "Experimental", 
                "description": "The interventions are administered in the randomized order."
            }, 
            {
                "arm_group_label": "Krill meal", 
                "arm_group_type": "Experimental", 
                "description": "The interventions are administered in the randomized order."
            }, 
            {
                "arm_group_label": "Fish oil", 
                "arm_group_type": "Active Comparator", 
                "description": "The interventions are administered in the randomized order."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to compare the acute bioavailability of two different krill oil\n      products called krill oil and krill meal in comparison to fish oil product."
        }, 
        "brief_title": "Bioavailability of Fatty Acids From Krill Oil and Krill Meal and Fatty Acids From Fish Oil in Healthy Subjects.", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy female and male\n\n          -  Age 18 - 65 years\n\n          -  Body mass index 18.5 - 30\n\n          -  Informed consent, signed\n\n        Exclusion Criteria:\n\n          -  Medication potential to affect the bioavailability of fatty acids (e.g.\n             lipid-lowering drugs)\n\n          -  Familial hypercholesterolemia, marked combined hyperlipidemia, condition that would\n             impair, fat absorption (e.g. chronic pancreatitis, pancreatic lipase deficiency\n             syndrome)\n\n          -  Any untreated medical condition affecting absorption of fat\n\n          -  Type 1 and 2 diabetes\n\n          -  Cancer or other malignant disease within past five years\n\n          -  Periodical hormone replacement therapy\n\n          -  High intake of oily fish (once a week or more) (i.e. salmon, herring, sardines,\n             mackerel, vendace)\n\n          -  Smoking\n\n          -  Alcohol consumption > 15 doses per week\n\n          -  Females who are pregnant, breast-feeding or intend to become pregnant\n\n          -  Hypersensitivity to any of the components of the test product\n\n          -  Regular use of n-3 supplements 4 weeks before randomization\n\n          -  Lack of suitability for participation in the trial, for any medical reason, as judged\n             by the principal investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "19", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02089165", 
            "org_study_id": "RISU 58/2013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Krill oil", 
                "description": "Krill oil from Antarctic krill, per oral, capsule, targeted daily n-3 PUFA dose of 1 700 mg, single administration", 
                "intervention_name": "Krill oil", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Krill meal", 
                "description": "Krill meal, granular meal from Antarctic krill, per oral, targeted daily n-3 PUFA dose of 1 700 mg, single administration", 
                "intervention_name": "Krill meal", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Fish oil", 
                "description": "Fish oil, per oral, capsule, targeted daily n-3 PUFA dose of 1 700 mg, single administration", 
                "intervention_name": "Fish oil", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kuopio", 
                    "country": "Finland", 
                    "zip": "70210"
                }, 
                "name": "Oy Foodfiles Ltd, memeber of Foodfiles group"
            }
        }, 
        "location_countries": {
            "country": "Finland"
        }, 
        "number_of_arms": "3", 
        "official_title": "Randomized, Single-center, Open-label, Blinded Endpoint Assessment Study (Cross-over Study With 3 Study Products) on Bioavailability of Fatty Acids (Plasma Lipid Fractions) From Krill Oil and Krill Meal and Fatty Acids From Fish Oil in Healthy Subjects.", 
        "other_outcome": {
            "measure": "Mean proportions of fatty acids in plasma phospholipids and triglycerides.", 
            "safety_issue": "No", 
            "time_frame": "0-72 h"
        }, 
        "overall_official": [
            {
                "affiliation": "Oy Foodfiles Ltd, member of Foodfiles group", 
                "last_name": "Essi S Sarkkinen, Ph.D", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Oy Foodfiles Ltd, memeber of Foodfiles group", 
                "last_name": "Sakari A Nieminen, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Finland: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Incremental 0-72 h area under the curve of EPA + DHA proportion in plasma phospholipids.", 
            "safety_issue": "No", 
            "time_frame": "0-72 h"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02089165"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Incremental 0-72 h area under the curve of EPA + DHA proportion in plasma triglyceride.", 
            "safety_issue": "No", 
            "time_frame": "0-72 h"
        }, 
        "source": "Olympic Seafood AS", 
        "sponsors": {
            "collaborator": {
                "agency": "Oy Foodfiles Ltd", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Olympic Seafood AS", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}